SQI Diagnostics to Extend Warrant Expiry Date

SQI Diagnostics to Extend Warrant Expiry Date

SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today that it has received approval from the TSX Venture Exchange to extend the expiry of 1,140,000 outstanding common share purchase warrants (the “Warrants”) of the Company, which were issued in connection with the Company’s August 12, 2010 private placement financing.

Each Warrant, as amended, entitles the holder thereof to purchase one common share of the Company at any time until the close of business on August 12, 2012 at an exercise price of $5.00 per common shares. The Warrants will be amended, effective July 30, 2011, to extend the term of such Warrants to August 12, 2013. All other provisions of the Warrants will remain the same.

SQI Diagnostics is a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit . The contents of the Company’s website are specifically not incorporated by reference in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.